Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    7,393 result(s) found. Displaying page 289 of 370.
    «« First « Previous 285  286  287  288  289  290  291  292  293  Next» Last»»
    EudraCT Number: 2017-001758-32 Sponsor Protocol Number: 20140114 Start Date*: 2017-08-29
    Sponsor Name:Amgen, Inc.
    Full Title: Long-term Safety Follow-up of Subjects With Giant Cell Tumour of Bone Treated With Denosumab in Study 20062004
    Medical condition: Giant Cell Tumour of Bone
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005153-37 Sponsor Protocol Number: LJ501-CRH04 Start Date*: 2018-07-11
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated w...
    Medical condition: Catecholamine-resistant hypotension associated with distributive shock
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) LT (Prematurely Ended) FR (Completed) ES (Temporarily Halted) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000746-19 Sponsor Protocol Number: LP0162-1337 Start Date*: 2018-11-06
    Sponsor Name:LEO Pharma A/S
    Full Title: An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab c...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) BE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004686-39 Sponsor Protocol Number: EFC14462 Start Date*: Information not available in EudraCT
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa in Treatment naïve Pediatric Participan...
    Medical condition: Glycogen storage disease type II
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) Outside EU/EEA ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000415-87 Sponsor Protocol Number: 208467 Start Date*: 2019-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ES...
    Medical condition: Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Completed) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-003265-36 Sponsor Protocol Number: AG348-C-022 Start Date*: 2022-05-10
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly T...
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) CZ (Trial now transitioned) DK (Trial now transitioned) IT (Prematurely Ended) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018072-33 Sponsor Protocol Number: UKM08_0057 Start Date*: 2011-08-01
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours
    Medical condition: Intracranial Germ Cell tumours of any histology and intracranial site and dissemination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065853 Nongerminomatous germ cell tumor of the CNS LLT
    20.0 100000004864 10018207 Germinoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed) FR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003370-35 Sponsor Protocol Number: MCT8-2019-2 Start Date*: Information not available in EudraCT
    Sponsor Name:Rare Thyroid Therapeutics International AB
    Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
    Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006158-16 Sponsor Protocol Number: UMCN-AKF08.02 Start Date*: 2009-02-13
    Sponsor Name:Radboud university medical center
    Full Title: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
    Medical condition: HIV-infection in pregnant women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020173 10020175 HIV infection with other conditions LLT
    Population Age: Newborns, Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001476-37 Sponsor Protocol Number: PENTA17 Start Date*: 2015-12-16
    Sponsor Name:Fondazione PENTA ONLUS
    Full Title: SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ...
    Medical condition: Paediatric HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005427-20 Sponsor Protocol Number: C4601003 Start Date*: 2022-07-13
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISE...
    Medical condition: Prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age by active immunization
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025169 Lyme disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) EE (Prematurely Ended) FI (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000214-42 Sponsor Protocol Number: 755-201-EB Start Date*: Information not available in EudraCT
    Sponsor Name:InMed Pharmaceuticals Inc.
    Full Title: A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa.
    Medical condition: Epidermolysis bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GR (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-001286-20 Sponsor Protocol Number: CABL001I12201 Start Date*: 2021-07-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP...
    Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    21.0 100000004864 10060498 Juvenile chronic myeloid leukemia LLT
    24.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001084-71 Sponsor Protocol Number: B7981032 Start Date*: 2020-06-01
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, New York
    Full Title: A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) HU (Completed) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001929-32 Sponsor Protocol Number: 2014/2126 Start Date*: 2014-08-25
    Sponsor Name:Gustave Roussy
    Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
    Medical condition: Diffuse Intrinsic Pontine Glioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-002473-21 Sponsor Protocol Number: ERGCR-18-ORGHIT-001 Start Date*: 2019-03-05
    Sponsor Name:Aspen Global Incorporated
    Full Title: An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
    Medical condition: Acute Heparin-induced Thrombocytopenia (HIT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10062506 Heparin-induced thrombocytopenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) PL (Completed) ES (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003662-41 Sponsor Protocol Number: MW-2004-11-02 Start Date*: 2005-11-24
    Sponsor Name:MediWound Ltd
    Full Title: Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)
    Medical condition: Burn wounds defined as deep partial thickness or full thickness thermal burns.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003314-13 Sponsor Protocol Number: P1200_11 Start Date*: 2013-03-25
    Sponsor Name:Cliniques Universitaires Saint Luc, Université catholique de Louvain
    Full Title: RING – RItuximab for lupus Nephritis with remission as a Goal, an investigator-initiated randomized international open multicentric study
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Ongoing) AT (Completed) PT (Completed) ES (Ongoing) DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004225-24 Sponsor Protocol Number: CNTO1275CRD3004 Start Date*: 2021-03-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance i...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-000669-35 Sponsor Protocol Number: MK-3475-716 Start Date*: 2018-10-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
    Medical condition: High-risk Stage II melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 285  286  287  288  289  290  291  292  293  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 07:07:15 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA